ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Recruiting · NCT06364774 · Registry updated 2026-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT06364774 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Children's Hospital of Philadelphia | 215 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |